Skip to main content
News and Events banner photo

News & Events
Stay Informed with Industry Insights and Follow Our Progress

Scientist in background holding filled vial in foreground

Filter

Company News

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

November 2, 2023
Findings support saRNA as a therapeutic strategy to compensate dystrophin’s function by upregulating UTRN expression…
Company NewsNews Highlight

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

June 10, 2023
Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically validate Ractigen’s…
Company News

Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS

June 10, 2023
Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically…
Company News

Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

March 3, 2023
Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…
Company News

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

January 27, 2022
Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million…
Company News

Ractigen Therapeutics closes on $17 Million Series A to advance lead program into clinical phase, led by Hillhouse Venture Capital

February 10, 2021
Ractigen Therapeutics, a leading company in the saRNA drug space, announced that it has closed…
Close Menu